Company Overview and News


Add MNKD
to your dashboard

Headline News

MannKind - Afrezza Scripts Start Out 2018 Modestly

2018-01-13 seekingalpha
MannKind (MNKD) investors were hoping to see Q1 of 2018 be a defining quarter for the sales of Afrezza. The start of the year has been very modest with script sales coming in at just 345 for a week that included a New Year's holiday, record cold, and some severe weather in certain regions of the country. That being said, sales growth needs to happen if MannKind is going to demonstrate to the Street, potential investors, and potential partners that Afrezza is commercially viable. (67-0)

Short Sellers Grow More Selective on Major Biotechs

2018-01-11 247wallst
The short interest data are out for the most recent settlement date, December 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-0)

MannKind Closes Out 2017 - Looking At Scripts And Guidance

2018-01-11 seekingalpha
MannKind (MNKD) closed out 2018 with some modest progress, but still has a long way to go in delivering the types of numbers that will impress the street, individual investors, or even a potential partner. The stage is now set for a binary event in Q1 relating to cash, and the company needs to post some impressive sales numbers sooner rather than later. (67-0)

Bet Against Synergy Pharmaceuticals Inc Stock Has Paid off — for Now

2018-01-10 investorplace
Last year, prospects for Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) looked promising, until markets grew risk-adverse for small-cap biotechnology companies. Even though prescription growth neared 100% month-over-month since the launch of its main drug, Trulance, investors, and analysts grew less confident of SGYP stock. It fell steadily in the second-half of last year while the short-selling position accumulated in a big way. (308-5)

MannKind - Afrezza Scripts Crack 500

2017-12-29 seekingalpha
MannKind (MNKD) investors let out a bit of a Bronx cheer this week as Afrezza scripts surpassed the 500 mark for the first time since MannKind assumed full responsibility for marketing the inhaled insulin, and for the first time since Sanofi accomplished that script level in December of 2015. During the past year Afrezza spent 22 weeks in the 200's, 14 weeks in the 300's, and 14 weeks in the 400's before cracking the 500 mark as 2017 closed out. (67-0)

MannKind: Still Looking Weak

2017-12-28 seekingalpha
MannKind Corporation (NASDAQ:MNKD) continues with its difficult times as its operating and stock market performance continues to decline. Apart from label expansion for Afrezza, the company did not post any positive development. Its revenue continued to decline despite some gains showed by Afrezza. The company also kept burning through its cash for meeting operating and marketing expenses and may now have to go for stock issue for shoring up its finances. (67-0)

Major Biotechs See Surge in Short Interest

2017-12-28 247wallst
The short interest data are out for the most recent settlement date, December 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-0)

Do Options Traders Know Something About MannKind Corp (MNKD) Stock We Don't?

2017-12-26 zacks
Investors in MannKind Corporation (MNKD - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 29th, 2017, $3.00 Call had some of the highest implied volatility of all equity options today. (83-1)

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

2017-12-23 seekingalpha
Today we will focus on Biogen’s (BIIB) announcement regarding BAN2401, the company’s Alzheimer’s candidate in mid-stage study. (227-3)

MannKind - Scripts, Deerfield, And Insider Buys

2017-12-23 seekingalpha
There is a dynamic taking shape that MannKind (NASDAQ:MNKD) investors should be considering. Earlier in Q4, MannKind negotiated with Deerfield on some debt issues. Included in that negotiation was an extension of a $10 million payment due to Deerfield from October 31st to January 15th of 2018. A part of that deal was that MannKind would place $10 million in an escrow account. Deerfield holds the option to convert the payment to shares in lieu of cash. (67-1)

MannKind: The Postmortem Is Available

2017-12-18 seekingalpha
With no positive trajectory, no incredible opportunity, and no significant growth tells the story of MannKind's future. (75-0)

MannKind - Afrezza Scripts Flat As Average Revenue Per Reported Script Stabilizes

2017-12-16 seekingalpha
Sales of Afrezza from MannKind (MNKD) came in flat for the week of December 8th. Script sales are tracking within y projections even with a label change 5 weeks ago and regional television advertising starting a month ago. The fourth quarter of the year, which is packed with holidays, is always a bit of a tough quarter for pharma sales. (67-1)

MannKind Shareholders Approve Additional Shares - What Investors Need To Consider

2017-12-14 seekingalpha
MannKind (MNKD) investors have approved the authorization of an additional 140,000,000 shares in a special meeting held on December 13th. With these new shares the company now has an authorized share count of 280,000,000. The newly minted shares are not immediate dilution. Dilution happens if shares are issued. A term that investors may want to become familiar with is "Fully Diluted Share Count". This term essentially gives consideration to the full amount of shares authorized. (67-0)

MannKind - Shareholder Vote On More Shares Is Center Stage

2017-12-13 seekingalpha
MannKind (MNKD) investors will be making what is likely their most important voting decision on December 13th. MannKind is hosting a special meeting to seek shareholder approval on authorizing 140,000,000 new shares. This would double the authorized share count to 280,000,000. (67-0)

Major Biotechs See Rising Tide in Short Interest

2017-12-12 247wallst
The short interest data are out for the most recent settlement date, November 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-0)

Stock Research Report

MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes. Its only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the FDA on June 27, 2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, 30.3 million people in the United States had diabetes in 2015. Globally, the International Diabetes Federation has estimated that approximately 415.0 million people had diabetes in 2015 and approximately 642.0 million people will have diabetes by 2040.

Afrezza is a rapid-acting inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Administered at the...

Click for full article
CUSIP: 56400P201